Brensocatib for treating moderate to severe non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2013
Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 August 2025